SS-31 — Peptide Dosing Protocols reference

patient_educationexpert_opinion · status: needs_provider_review

Details

Author: —

Citation: —

Summary (generated — provider review required)

SS-31 Peptide Dosing Guide: Elamipretide Protocol & Safety (2026) Shop Protocols Stacks A–Z Index Email Updates Home Protocols SS-31 Dosing Guide: Elamipretide Protocol & Safety (2026) Protocol / Research Dosing Guide SS-31 Dosing Guide: Elamipretide Protocol & Safety (2026) An evidence-based SS-31 protocol guide covering dosing structure, timing, reconstitution, and safety considerations for this mitochondria-targeted peptide. By Garret Grant · Founder & Lead Researcher · Last reviewed June 2026 · Share Supplier Pick Copy code PEPPAL Copy code PEPPAL Verified Supplier Verified Supplier Peptide Partners SS-31 50 mg Vials View 50 mg vials Table of Contents View Supplies Quick Start Dosing Protocol & Schedule Supplies Needed Reconstitution Guide Mechanism Who Should Avoid It Side Effects & Safety Timeline & Monitoring Clinical Evidence Storage & Handling Troubleshooting Regulatory Status SS-31 Comparisons Related Protocols Blood Tests FAQ References SS-31 Quick Start SS-31 is a synthetic four-amino-acid peptide. It moves into the inner mitochondrial membrane and binds a phospholipid called cardiolipin, which is the structural scaffold the mitochondria use to pack their energy-making machinery.

The original source document remains the source of truth. Generated summaries are not authoritative.

Linked assets (10) · phenotypes (1)

evidence_reference, dosing_reference, safety_reference, mechanism, contraindication_reference, monitoring_reference

Phenotypes: mitochondrial_dysfunction

Findings (233) · awaiting review (195)

regulatory · pending

Both are usually discussed in mitochondrial-research contexts, but the evidence bases are very different — SS-31 has FDA-approved status for one disease; MOTS-c does not.

dosing · pending

Community pattern Common anti-aging / mitochondrial support Reported dose 1-5 mg Frequency / duration Once daily for 4-8 weeks Context and caveats Most consistent community-report cluster from forum aggregation and Reddit-style experience threads.

dosing · pending

Still far below clinical 40 mg/day dosing and not validated in healthy adults.

dosing · pending

Community pattern Guide-page standard range Reported dose 5-10 mg Frequency / duration Once daily, often morning Context and caveats Repeated by community-facing protocol sites as a general research-use range.

dosing · pending

Community pattern Performance-oriented reports Reported dose 10-20 mg Frequency / duration Once daily or pre-workout; often 4-12 weeks Context and caveats Appears on community protocol pages and some forum reports for athletic-performance framing.

dosing · pending

Frequency / duration Once daily; 12+ weeks in trials / ongoing per label Context and caveats This is the Forzinity/TAZPOWER Barth-syndrome dose, not a fitness-community dose.

dosing · pending

The only published human-trial structure is continuous daily 40 mg SC for Barth syndrome.

dosing · pending

By Garret Grant · Founder & Lead Researcher · Last reviewed June 2026 · Share Supplier Pick Copy code PEPPAL Copy code PEPPAL Verified Supplier Verified Supplier Peptide Partners SS-31 50 mg Vials View 50 mg vials Table of Contents View Supplies Quick Start Dosing Protocol & Schedule Supplies Needed Reconstitution Guide Mechanism Who Should Avoid It Side Effects & Safety Timeline & Monitoring Clinical Evidence Storage & Handling Troubleshooting Regulatory Status SS-31 Comparisons Related Protocols Blood Tests FAQ References SS-31 Quick Start SS-31 is a synthetic four-amino-acid peptide.

regulatory · pending

The FDA-approved bra

regulatory · pending

Two very different real-world contexts Forzinity (FDA-approved drug): A prescription product approved on September 19, 2025 under accelerated approval to improve muscle strength in adult and pediatric patients with Barth syndrome who weigh at least 30 kg.

dosing · pending

Comes as a 280 mg / 3.5 mL (80 mg/mL) ready-to-use solution.

dosing · pending

Dosing, storage, and labeling are set by the FDA-approved package insert.

dosing · pending

Research-use SS-31 vials: Lyophilized peptide sold by research suppliers, usually in 10 mg, 40 mg, or 50 mg vials, intended for laboratory research.

regulatory · pending

These are not FDA-approved medicines and have no human-use indication.

dosing · pending

Route Subcutaneous injection.

dosing · pending

The Forzinity label and TAZPOWER trial both used daily subcutaneous dosing.

dosing · pending

Trial-context dose 40 mg subcutaneously once daily was the studied arm and is now the Forzinity recommended dose for patients ≥30 kg.

dosing · pending

Frequency Once daily, same time each day per Forzinity label.

regulatory · pending

Research status FDA-approved for Barth syndrome only.

regulatory · pending

Information about Forzinity (elamipretide) reflects the FDA-approved la

dosing · pending

Peptide Dosing Protocols reports trial-context and FDA-label dosing for educational reference only.

dosing · pending

Headache, especially in the first weeks of dosing.

dosing · pending

We do not publish dosing or cycle instructions for healthy-adult use of SS-31, because no such use has been studied in a published human trial.

dosing · pending

SS-31 Dosing Protocol & Schedule Dosing information for SS-31 comes from two distinct contexts.

regulatory · pending

The first is the FDA-approved Forzinity label for Barth syndrome.

regulatory · pending

The second is the TAZPOWER clinical trial, which is the published Phase 2/3 study Forzinity was approved on.

dosing · pending

Both used the same daily 40 mg subcutaneous dose.

dosing · pending

This is not a dosing recommendation.

dosing · pending

SS-31 Dosing Reference Tabs Choose the source you are researching to see the matching label or trial-context information.

regulatory · pending

Forzinity (FDA Label) TAZPOWER (Trial Context) Community-Reported The current FDA-approved Barth-syndrome label as of June 2026.

regulatory · pending

Forzinity is approved to improve muscle strength in adult and pediatric patients with Barth syndrome weighing at least 30 kg.

outcome · pending

Approval is accelerated and based on improvement in knee extensor muscle strength, an intermediate clinical endpoint.

dosing · pending

Forzinity recommended dosage (per FDA label) Population Patients ≥30 kg Dose 40 mg Route Subcutaneous, once daily Notes Same time each day.

dosing · pending

Skip a missed dose; do not doub

dosing · pending

Population Adults with severe renal impairment (eGFR 30 mL/min, not on dialysis) Dose 20 mg Route Subcutaneous, once daily Notes Per FDA label dose adjustment.

dosing · pending

Population Adults with eGFR 30 mL/min and on dialysis Dose Not defined Route — Notes Insufficient information for a dosing regimen per label.

dosing · pending

Population Patients 30 kg Dose Not approved Route — Notes Safety and effectiveness not established.

dosing · pending

Population Dose Route Notes Patients ≥30 kg 40 mg Subcutaneous, once daily Same time each day.

dosing · pending

Skip a missed dose; do not double up.

Processing

Processed into 35 searchable sections.